Real-Life Analysis of Therapeutic Management and Its Correlation With the Dermatology Life Quality Index Score in 108 Patients With Pustular Psoriasis: An Italian Monocenter Study
Keywords:
generalized pustular psoriasis, palmoplantar pustular pustulosis, DLQI, Psoriasis, Biological TherapyAbstract
Introduction: Pustular psoriasis (PP) is a rare life-threatening skin disease with negatively impact on quality of life (QoL). Clinically, it may be systemic (generalized pustular psoriasis [GPP]) or localized on palms and soles (palmoplantar pustulosis [PPP]). It is not rare to observe plaque psoriasis associated with GPP.
Objective: We explored the therapies used for PP and their correlation with patient QoL scores, through a cross-sectional study using retrospective data from a monocentric database in the period 2017-2021.
Method: Patient characteristics were summarized using descriptive statistics and treatment predictors of QoL were identified by multiple regression analysis. Among 108 patients with PP, 57.4% had GPP + PSO whereas 42.6% had PPP. The therapeutic management is based on systemic conventional treatments and biological therapies in both GPP and PPP.
Results: GPP + PSO patients with an impaired QoL (DLQI≥10) were associated with biological therapy including certolizumab (OR=2.38), etanercept (OR=2.25), secukinumab (OR=2.03) or ustekinumab (OR=2.79) whereas, PPP patients were positively associated with secukinumab (OR=2.85) or apremilast (OR 4.28, 95%-CI 0.56-9.62).
Conclusion: Currently, systemic conventional therapy remains the therapeutic fulcrum of PP management. A great effect on QoL, especially for GPP+PSO, was assessed regardless the ongoing treatment and only newer biologic options were able to somehow positively impact.
References
Reich K, Augustin M, Gerdes S, et al. Generalized pustular psoriasis: overview of the status quo and results of a panel discussion. J Dtsch Dermatol Ges. 2022;20:753-771. DOI: 10.1111/ddg.14764. PMID: 35674482.
Reisner DV, Johnsson FD, Kotowsky N, Brunette S, Valdecantos W, Eyerich K. Impact of Generalized Pustular Psoriasis from the Perspective of People Living with the Condition: Results of an Online Survey. Am J Clin Dermatol. 2022;23(Suppl 1):65-71. DOI: 10.1007/s40257-021-00663-y.
Twelves S, Mostafa A, Dand N, et al. Clinical and genetic differences between pustular psoriasis subtypes. J Allergy Clin Immunol. 2019;143(3):1021-1026. DOI: 10.1016/j.jaci.2018.06.038.
Genovese G, Moltrasio C, Cassano N, Maronese CA, Vena GA, Marzano AV. Pustular Psoriasis: From Pathophysiology to Treatment. Biomedicines. 2021;9(12):1746. DOI: 10.3390/biomedicines9121746.
Zhou J, Luo Q, Cheng Y, Wen X, Liu J. An update on genetic basis of generalized pustular psoriasis (Review). Int J Mol Med. 2021;47(4):118. DOI: 10.3892/ijmm.2021.4951.
Mössner R, Wilsmann-Theis D, Oji V, et al. The genetic basis for most patients with pustular skin disease remains elusive. Br J Dermatol. 2018;178(3):740-748. DOI: 10.1111/bjd.15867.
Sugiura K, Muto M, Akiyama M. CARD14 c.526G>C (p.Asp176His) is a significant risk factor for generalized pustular psoriasis with psoriasis vulgaris in the Japanese cohort. J Invest Dermatol. 2014;134(6):1755-1757. DOI: 10.1038/jid.2014.46.
Li L, You J, Fu X, et al. Variants of CARD14 are predisposing factors for generalized pustular psoriasis (GPP) with psoriasis vulgaris but not for GPP alone in a Chinese population. Br J Dermatol. 2019;180(2):425-426. DOI: 10.1111/bjd.17392.
Menter A, Van Voorhees AS, Hsu S. Pustular Psoriasis: A Narrative Review of Recent Developments in Pathophysiology and Therapeutic Options. Dermatol Ther (Heidelb). 2021;11(6):1917-1929. DOI: 10.1007/s13555-021-00612-x.
Blair HA. Spesolimab: First Approval. Drugs. 2022;82(16):1681-1686. DOI: 10.1007/s40265-022-01801-4.
Morita A, Choon SE, Bachelez H, et al. Design of Effisayil™ 2: A Randomized, Double-Blind, Placebo-Controlled Study of Spesolimab in Preventing Flares in Patients with Generalized Pustular Psoriasis. Dermatol Ther (Heidelb). 2023;13(2):347-359. DOI: 10.1007/s13555-022-00835-6.
Iznardo H, Puig L. Exploring the Role of IL-36 Cytokines as a New Target in Psoriatic Disease. Int J Mol Sci. 2021;22(9):4344. DOI: 10.3390/ijms22094344.
Khanskaya I, Pinkstaff J, Marino MH, Savall T, Li J, Londei M. A Phase 1 Study of ANB019, an Anti-IL-36 Receptor Monoclonal Antibody, in Healthy Volunteers. AnaptysBio. 2018. Disponibile su: https://www2.anaptysbio.com/wp-content/uploads/ANB019-Phase-1-Study-Poster-EAACI-2018.pdf.
Burden AD, Choon SE, Gottlieb AB, Navarini AA, Warren RB. Clinical Disease Measures in Generalized Pustular Psoriasis. Am J Clin Dermatol. 2022;23(Suppl 1):39-50. DOI: 10.1007/s40257-021-00653-0.
Bhushan M, Burden AD, McElhone K, James R, Vanhoutte FP, Griffiths CE. Oral liarozole in the treatment of palmoplantar pustular psoriasis: a randomized, double-blind, placebo-controlled study. Br J Dermatol. 2001;145(3):546-553. DOI: 10.1046/j.1365-2133.2001.04411.x.
Scala E, Megna M, Amerio P, et al. Patients' demographic and socioeconomic characteristics influence the therapeutic decision-making process in psoriasis. PLoS One. 2020;15(8):e0237267. DOI: doi:10.1371/journal.pone.0237267.
Tosukhowong T, Kiratikanon S, Wonglamsam P, et al. Epidemiology and clinical features of pustular psoriasis: A 15-year retrospective cohort. J Dermatol. 2021;48(12):1931-1935. DOI: 10.1111/1346-8138.16164.
Pfohler C, Muller CS, Vogt T. Psoriasis vulgaris and psoriasis pustulosa: epidemiology, quality of life, comorbidities and treatment. Curr Rheumatol Rev. 2013;9(1):2-7. DOI:10.2174/1573397111309010002.
Lu J, Wang Y, Li Y, Gong Y, Ding Y, Shi Y. Comparative study on the clinical efficacy and safety of acitretin and MTX in the treatment of pustular psoriasis by TLR7/MyD88/CXCL16 pathway. Appl Bionics Biomech. 2022;2022:9640326. DOI: Published 2022 Mar 18. doi:10.1155/2022/9640326.
Wang WM, Jin HZ. Biologics in the treatment of pustular psoriasis. Expert Opin Drug Saf. 2020;19(8):969-980. DOI: 10.1080/14740338.2020.1785427.
Gottlieb AB, Kubanov A, van Doorn M, et al. Sustained efficacy of secukinumab in patients with moderate-to-severe palmoplantar psoriasis: 2.5-year results from GESTURE, a randomized, double-blind, placebo-controlled trial. Br J Dermatol. 2020;182(4):889-899. DOI: 10.1111/bjd.18331.
Miyachi H, Konishi T, Kumazawa R, et al. Treatments and outcomes of generalized pustular psoriasis: a cohort of 1516 patients in a nationwide inpatient database in Japan. J Am Acad Dermatol. 2022;86(6):1266-1274. DOI:10.1016/j.jaad.2021.06.008.
Hoegler KM, John AM, Handler MZ, Schwartz RA. Generalized pustular psoriasis: a review and update on treatment. J Eur Acad Dermatol Venereol. 2018;32(10):1645-1651. DOI: 10.1111/jdv.14949.
Raposo I, Torres T. Palmoplantar psoriasis and palmoplantar pustulosis: current treatment and future prospects. Am J Clin Dermatol. 2016;17(4):349-358. DOI: 10.1007/s40257-016-0191-7.
Husson B, Barbe C, Hegazy S, et al; Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie. Efficacy and safety of TNF blockers and of ustekinumab in palmoplantar pustulosis and in acrodermatitis continua of Hallopeau. J Eur Acad Dermatol Venereol. 2020;34(10):2330-2338. DOI: 10.1111/jdv.16265.
Ferrières L, Konstantinou MP, Bulai Livideanu C, et al. Long-term continuation with secukinumab in psoriasis: association with patient profile and initial psoriasis clearance. Clin Exp Dermatol. 2019;44(7):e230-e234. DOI: 10.1111/ced.13999.
Kearns DG, Chat VS, Zang PD, Han G, Wu JJ. Review of treatments for generalized pustular psoriasis. J Dermatolog Treat. 2021;32(5):492-494. DOI:10.1080/09546634.2019.1682502.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Dario Buononato, Emanuele Scala, Pierfrancesco Benvenuto, Stefano Caccavale, Eugenia Veronica Di Brizzi, Roberta Di Caprio, Giuseppe Argenziano, Anna Balato

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Dermatology Practical & Conceptual applies a Creative Commons Attribution License (CCAL) to all works we publish (http://creativecommons.org/licenses/by-nc/4.0/). Authors retain the copyright for their published work.